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Abstract
Background: To describe an episode of thyroid associated orbitopathy (TAO) following the
initiation of thiazolidinedione (TZD).
Case presentation: We report a female patient with a history of Graves' disease and stabilised
thyroid associated orbitopathy for 2.5 years, who experienced rapid progression of TAO after the
initiation of thiazolidinedione for glycemic control. Following the discontinuation of TZD, the
patient experienced subsequent stabilisation of disease and normalization of vision. The medical
history, ophthalmic findings, and clinical course are discussed.
Conclusion: Thiazolidinediones may exacerbate TAO, and this should be taken into consideration
when selecting treatment for diabetic patients with a history of autoimmune thyroid disorders.
Background
The thiazolidinediones (TZDs) are among one of several
classes of oral hypoglycemic agents commonly utilized to
maintain glycemic control in patients with type 2 diabetes
mellitus. While the mechanism by which TZDs increase
the action of insulin is not precisely known, these agents
have been shown to be potent agonists of the nuclear hor-
mone receptor, peroxisome proliferator activated recep-
tor-γ (PPAR-γ), which is found predominantly in adipose
tissue and plays a dominant role in adipocyte differentia-
tion [1]. A primary cause of proptosis in thyroid associ-
ated orbitopathy is the expansion of adipose tissue
volume in the orbit. We report a case of a female patient
with a history of Graves' disease and stabilized TAO, who
experienced rapid progression of proptosis following ini-
tiation of rosiglitazone for glycemic control. This study
was performed in accordance with the Declaration of
Helsinski.
Case presentation
In February 2005, a 56-year-old female smoker presented
to our clinic for follow-up of her Graves' disease. Eyelid
retraction was noted two years prior to presentation, but
she reported no proptosis or other signs of TAO. She was
diagnosed with hyperthyroidism in August 2004 and had
been stabilized on propranolol and propylthiouracil. In
November 2004, the patient was placed on rosiglitazone/
metformin for glycemic control. Over the next several
months thereafter, the patient reported development of
diplopia on upgaze and rapid progression of proptosis,
particularly in the left eye. She also noticed an increase in
abdominal girth and a greater amount of subcutaneous fat
in her abdomen, chest, and back.
On clinical examination we noted evidence of eyelid
retraction and severe proptosis, with Hertel measure-
ments of 25 mm on the right and 28 mm on the left (Fig-
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ure 1B). Extraocular motility was within normal limits,
and visual acuity without correction was 20/40 in both
eyes. Intraocular pressure was within normal limits, and
there were no signs of exposure keratopathy. There was
evidence of a subtle optic neuropathy on the left with
mild red color desaturation and an afferent pupillary
defect. Thyroid function tests showed a euthyroid state.
An elevation of TBII was noted, but other thyroid autoan-
tibody screens were negative.
Treatment with rosiglitazone/metformin was discontin-
ued, and the patient was started on metformin and glipiz-
ide to maintain glycemic control. There had been
consideration by her medical team to utilize I131 to radi-
oactively ablate the thyroid gland. However, given the
possibility of transiently worsening her thyroid-related
orbitopathy, the decision was made to pursue medical
management with propranolol and propylthiouracil.
On 6-week follow-up, there was no progression of disease
(Figure 1C). Hertel measurements were 26 mm on the
right and 29 mm on the left, and her vision remained sta-
ble, with resolution of the pupillary defect. MRI of the
orbits performed in April 2005 revealed expansion of the
orbital fat compartment and mild enlargement of the
inferior rectus muscles on each side (Figure 2). Of note,
the patient was found to have a right thyroid nodule,
which, on cytological examination of samples obtained
by fine-needle aspiration, revealed atypical cells. She pro-
ceeded to have a right hemithyroidectomy for further
management. Microscopic analysis of surgical specimen
revealed papillary carcinoma, predominantly follicular
variant, which had been completely excised.
Following partial thyroidectomy, early synthroid replace-
ment was initiated to prevent hypothyroidism and possi-
ble deterioration of her TAO. Based on her MRI findings
and profound proptosis on the left side, the decision was
made to proceed with orbital decompression surgery prior
to further treatment of the papillary cancer with I131 abla-
tion. Physical examination findings were unchanged, with
Hertel measurements 25 mm on the right and 29 mm on
the left (Figure 1D).
Discussion
TAO is a common cause of proptosis [2]. Exacerbation of
TAO, however, is uncommon once the stable phase of the
condition is reached, and causes of flare ups are not well
understood but may include I131 treatment, hypothy-
roidism, and smoking [3-5].
A well-known side effect of TZDs is an increase in subcu-
taneous fat [1]. Recent studies have suggested a link
between the expression of the thyroid stimulating hor-
mone receptor (TSHr) and adipogenesis in the orbital tis-
sues of patients with TAO [6,7]. Specifically, the activation
of PPAR-γ by its agonist, TZD, was shown to stimulate
functional TSHr expression, and also to induce the recruit-
ment and differentiation of orbital fibroblasts into mature
lipid-laden adipocytes [7-9]. This potential for preadi-
pocyte differentiation is shared with abdominal subcuta-
neous tissue. Other studies have shown that the
expression of PPAR-γ was greater in adipose and connec-
tive tissue from patients during the active stages of TAO
[10,11]. These results suggest that TSHr expression in
orbital fibroblasts may be linked to adipogenesis, and that
the activation of the PPAR-γ, such as by TZD, may play an
important role in the stimulation of adipogenesis and the
pathogenesis of TAO.
A. Patient, previous photograph prior to initiation of TZD Figure 1
A. Patient, previous photograph prior to initiation of TZD. B. 
Patient, on initial visit, with evidence of eyelid retraction and 
severe proptosis. C. Patient, at six-week follow-up visit. D. 
Patient, at 3 month follow-up visit.
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These findings, in addition to the temporal profile of this
patient's TAO exacerbation, the development of TAO
about 24 months after her initial dysthyroid state whilst
euthyroid, and the subsequent stabilisation of proptosis
following discontinuation of the rosiglitazone, suggest
that the TZD may have had a role in the pathogenesis of
this patient's proptosis. Similar cases of thyroid eye dis-
ease exacerbation following the initiation of TZD have
been reported in the literature [12,13], and a recent study
by Dorkhan et al. showed that a subgroup of patients with
type 2 diabetes mellitus treated with pioglitazone
responded with increased eye protrusion [14]. Although
TAO can occur this late after the initial systemic diagnosis,
we believe the temporal association, in addition to the
patient's other body habitus changes, strongly suggest a
role of rosiglitazone in this case. These studies also suggest
that potential therapies for TAO may be directed towards
inhibition of the adipogenic pathway through the use of a
PPAR-γ inhibitor, although the detrimental metabolic
effects should be considered, and that PPAR-γ expression
could potentially be utilized as a marker for TAO disease
activity [7,8].
Conclusion
TZDs are a commonly utilized hypoglycemic agent in the
treatment of diabetes mellitus, and their precise roles in
fat metabolism continue to be elucidated. As agonists of
the PPAR-γ, its effects may have important implications in
the selection of treatment modalities for patients with dia-
betes, and it will be important to be aware of potential
problems in patients with a history of autoimmune thy-
roid disorders, even in those without obvious evidence of
TAO.
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